DePuy Synthes Announces Agreement with Prosidyan to Promote FIBERGRAFT

DePuy Synthes,* part of the Johnson & Johnson Medical Devices Companies,** has announced an exclusive agreement in the United States between DePuy Synthes Sales Inc. and Prosidyan to promote the FIBERGRAFT Family of Products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for optimal resorption in clinical use during spine fusion surgery. By adding FIBERGRAFT to its offerings, DePuy Synthes will further enhance the company’s biomaterials portfolio for spine, which currently includes cellular allograft, demineralized bone matrix and first generation synthetic solutions. Surgeons will now have a broad range of handling options based on the needs of each patient and surgical case.
 
Approximately 400,000 U.S. patients undergo spinal fusion surgery annually to help reduce pain and nerve root inflammation.¹ Surgeons will often use a biomaterial to facilitate bone growth and fusion. Each case is unique, and providing a broad portfolio of offerings allows surgeons the opportunity to select the right consistency.
 
“Our exclusive agreement with Prosidyan allows us to complete our biomaterials offering through a next-generation synthetic solution and provide our customers with a variety of options based on handling preference and needs of their patients,” said Juan-José Gonzalez, president, DePuy Synthes U.S. “This offering allows us to provide a more complete solution for our customers.”
 
Prosidyan was founded in 2009 to develop a family of synthetic bioactive bone graft substitutes based on microsized fibers of bioactive glass. Prosidyan’s first product, FIBERGRAFT BG Morsels, a synthetic bone graft substitute, received U.S. Food and Drug Administration (FDA) clearance in March 2014, and the first surgery utilizing this innovative bone substitute was performed in May 2014. The firm’s second product in the line, FIBERGRAFT BG Putty, received FDA clearance in March 2015, and comprises FIBERGRAFT BG Morsels delivered through Prosidyan’s proprietary bioactive carrier, OSSIGLIDE. Prosidyan’s third and flagship product FIBERGRAFT BG Matrix, received FDA clearance in October of 2017 and comprised FIBERGRAFT BG Morsels combined with Prosidyan’s proprietary type I collagen based bioactive carrier.
 
To date, FIBERGRAFT products have been provided for more than 10,000 patients across the United States.
 
DePuy Synthes is expected to begin promoting FIBERGRAFT in Q2 2018.

The Johnson & Johnson Medical Devices Companies represent a breadth of products, services, programs and research and development capabilities in surgical technology, orthopedics, and interventional solutions with an offering directed at delivering clinical and economic value to healthcare systems worldwide.
 
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to healthcare systems worldwide.
 
*DePuy Synthes represents the products and services of DePuy Synthes Inc. and its affiliates.

**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopedics, and interventional businesses within Johnson & Johnson’s Medical Devices segment.

Reference
1. Rajaee, Ss et al. Spinal fusion in the United States: analysis of trends from 1998 to 2008. Spine. 2012 Jan 1;37(1):67-76.